Oncoinvent ASA ONCIN
OSL · Norway · Health Technology
NOK 82.80-0.40 (-0.48%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Oncoinvent ASA (STU:7BG) advances lead candidate Radspherin with strong recruitment and FDA fast track designation, while preparing for a larger phase 3 trial.
Oncoinvent, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces the publication of clinical dosimetry data for Radspherin® in the Journal of Nuclear Medicine, one of the leading peer-reviewed journals in the field.
Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.